RSS feed

Publications by Anette Løken Eilertsen

14 publications found

Original articles

Eilertsen AL, Dahm AEA, Høibraaten E, Lofthus CM, Mowinckel MC, Sandset PM (2019)
Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment
Blood Coagul Fibrinolysis, 30 (1), 17-23
DOI 10.1097/MBC.0000000000000784, PubMed 30507711

Jacobsen AF, Kristiansen A, Bjørge L, Henriksen T, Eilertsen AL, Sandset PM (2014)
[Anticoagulation for venous thrombosis in pregnancy]
Tidsskr Nor Laegeforen, 134 (9), 926
DOI 10.4045/tidsskr.13.1605, PubMed 24828717

Dahm AE, Eilertsen AL, Goeman J, Olstad OK, Ovstebø R, Kierulf P, Mowinckel MC, Skretting G, Sandset PM (2012)
A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women
Thromb Res, 130 (1), 45-51
DOI 10.1016/j.thromres.2011.12.009, PubMed 22217510

Opstad TB, Eilertsen AL, Høibraaten E, Skretting G, Sandset PM (2010)
Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy
Blood Coagul Fibrinolysis, 21 (6), 516-21
DOI 10.1097/MBC.0b013e32833a06cd, PubMed 20453636

Sandset PM, Høibraaten E, Eilertsen AL, Dahm A (2009)
Mechanisms of thrombosis related to hormone therapy
Thromb Res, 123 Suppl 2, S70-3
DOI 10.1016/S0049-3848(09)70015-5, PubMed 19217481

Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM (2008)
Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers
J Thromb Haemost, 6 (6), 928-34
DOI 10.1111/j.1538-7836.2008.02970.x, PubMed 18394014

Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM (2008)
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method
BJOG, 115 (6), 773-9
DOI 10.1111/j.1471-0528.2008.01690.x, PubMed 18355366

Andresen MS, Eilertsen AL, Abildgaard U, Sandset PM (2007)
Hormone therapy and raloxifene reduce the coagulation inhibitor potential
Blood Coagul Fibrinolysis, 18 (5), 455-60
DOI 10.1097/MBC.0b013e32813a2de7, PubMed 17581320

Eilertsen AL, Liestøl S, Mowinckel MC, Hemker HC, Sandset PM (2007)
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system
Thromb Haemost, 97 (6), 938-43
DOI 10.1160/TH06-11-0632, PubMed 17549295

Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM (2006)
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis
Thromb Res, 120 (3), 371-9
DOI 10.1016/j.thromres.2006.10.013, PubMed 17156824

Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM (2006)
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation
Maturitas, 55 (3), 278-87
DOI 10.1016/j.maturitas.2006.04.012, PubMed 16713143

Eilertsen AL, Høibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM (2005)
The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis
Maturitas, 52 (2), 111-8
DOI 10.1016/j.maturitas.2005.01.004, PubMed 16186073

Other articles

Negaard HF, Eilertsen AL, Dahm A, Iversen PO, Østenstad B, Sandset PM (2006)
Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?
J Clin Oncol, 24 (17), 2683-4; author reply 2684
DOI 10.1200/JCO.2006.06.4345, PubMed 16763285

Theses

Eilertsen AL (2009)
Postmenopausal hormone therapy: differential impact of dose and regimens on hemostasis and inflammation
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 821, 1 b. (flere pag.)
BIBSYS 093605757, ISBN 978-82-8072-950-7